Sign in
4

Changes in Ownership

Axsome Therapeutics, Inc. Filed Acc 0001193125-25-267467

Chief Executive Officer sold 163,939 shares at an average $133.07 ($21,815,669)

  • Chief Executive Officer acquired 163,939 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
TABUTEAU HERRIOT Chief Executive Officer 2025-11-03 Option exercise 10b5-1 +91,705 $8.02 $735,474 98,934 D: show line 1 in the form
TABUTEAU HERRIOT Chief Executive Officer 2025-11-03 Sale 10b5-1 −91,705 $132.34 $12,136,240 7,229 D: show line 2 in the form
TABUTEAU HERRIOT Chief Executive Officer 2025-11-04 Option exercise 10b5-1 +50,459 $8.02 $404,681 57,688 D: show line 3 in the form
TABUTEAU HERRIOT Chief Executive Officer 2025-11-04 Sale 10b5-1 −50,459 $133.79 $6,750,910 7,229 D: show line 4 in the form
TABUTEAU HERRIOT Chief Executive Officer 2025-11-05 Option exercise 10b5-1 +21,775 $8.02 $174,636 29,004 D: show line 5 in the form
TABUTEAU HERRIOT Chief Executive Officer 2025-11-05 Sale 10b5-1 −21,775 $134.49 $2,928,520 7,229 D: show line 6 in the form
Open-market sales · 163,939 sh · avg $133.07 · $21,815,669

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
TABUTEAU HERRIOT Chief Executive Officer 2025-11-03 Option exercise · Stock Option (Right to Buy) 10b5-1 −91,705 324,031 D: show line 7 in the form
TABUTEAU HERRIOT Chief Executive Officer 2025-11-04 Option exercise · Stock Option (Right to Buy) 10b5-1 −50,459 273,572 D: show line 8 in the form
TABUTEAU HERRIOT Chief Executive Officer 2025-11-05 Option exercise · Stock Option (Right to Buy) 10b5-1 −21,775 251,797 D: show line 9 in the form
Loading xslF345X05/ownership.xml…